Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third Dose COVID-19 Vaccine Booster Following Two Doses of Inactivated Vaccines
NCT05095298Phase 4Unknown
- Sponsor
- Huashan Hospital
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 4, open-label trial in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Huashan Hospital. Primary endpoints: Immunogenicity of Third Dose Vaccine Booster at Day 28 and Reactogenicity of Third Dose Vaccine Booster at Day 28. Status: unknown.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05095298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095298.